AEMD Share Price Performance
US$2.73
-67.27 (-96.10%)
83.2% undervalued intrinsic discount
US$16.25
Fair Value
Price US$2.73
AnalystConsensusTarget US$16.25
Fair ValueUS$16.25
Share Pricen/a
New Narrative • Aug 16
Aethlon Medical, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
AEMD Community Narratives
AN
Fair Value
·Fair Value US$16.25 83.2% undervalued intrinsic discount
Oncology Trial Progress And Extracellular Vesicle Research Will Define Long Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Oncology Trial Progress And Extracellular Vesicle Research Will Define Long Term Upside
Aethlon Medical is trying to prove its blood-filtering device can help cancer patients by removing tiny particles linked to disease, and early signals are encouraging enough to keep the story alive. The next trial readouts and regulator feedback could open doors to bigger studies and new partners, but delays, weak results, or the need to raise more money could slow everything down.Read more
AN
US$16.25
83.2% undervalued intrinsic discount
Fair Value
Profit Margin
12.13%
Future PE
44.4x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Oncology Trial Progress And Extracellular Vesicle Research Will Define Long Term Upside
Fair Value: US$16.25 83.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Aethlon Medical, Inc. Key Details
About AEMD
- Founded
- 1984
- Employees
- 9
- CEO
- WebsiteView website
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
